Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2- metastatic breast cancer patients
Abstract Background Metastatic breast cancer (BC) is the main cause of cancer-related mortality in women worldwide. HR + /HER2- BC patients are treated with endocrine therapy (ET), but therapeutic resistance is common. The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with ET was a...
Saved in:
| Main Authors: | Miriam González-Conde, Celso Yáñez, Carmen Abuín, Corinna Keup, Ramón Lago-Lestón, Maribel Aybar, Lucía Pedrouzo, Patricia Palacios, Teresa Curiel, Juan Cueva, Carmela Rodríguez, Marta Carmona, Alexandra Cortegoso, Tomás García-Caballero, Laura Muinelo-Romay, Sabine Kasimir-Bauer, Rafael López-López, Clotilde Costa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06374-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01) -
Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01) -
An in silico and in vitro approach for understanding CDK2 expression pattern and prognostic implications in breast cancer
by: Fatima Manhas, et al.
Published: (2025-05-01) -
Identification of new inhibitors of the kinase activity of CDK2 and CDK9 by molecular modeling and high-efficiency screening
by: G.V. Andrianov, et al.
Published: (2021-12-01) -
Monitoring concentration and lipid signature of plasma extracellular vesicles from HR+ metastatic breast cancer patients under CDK4/6 inhibitors treatment
by: Mathilde Richard, et al.
Published: (2024-12-01)